Sugarbaker P H, Averbach A M, Jacquet P, Stuart O A, Stephens A D
Gastrointestinal Oncology Program, Washington Cancer Institute, Washington, DC, USA.
Surg Technol Int. 1996;5:245-9.
Dedrick et al. published a mathematical model in 1978 that described the theoretical rationale for in- traperitoneal administration of chemotherapeutic agents.' Numerous authors have provided substantial clinical and experimental evidence supporting Dedrick's model. Lukas et al.' and Torres et al.' have de- scribed the pharmacokinetics involved in the transport of drugs from the peritoneal cavity into the portal and systemic circulation. These investigations and others gave birth to the pharmacologic concept known as the peritoneal plasma barrier (PPB). The PPB has been described as a complex diffusion barrier, consisting of the endothelium, the mesothelium, and the intervening interstitium, along with the fluid in the blood and the dialysate.t This physiologic barrier limits the resorption of hydrophilic drugs such as mitomycinC, doxoru- bicin, and cisplatin from the peritoneal cavity into the blood.
德德里克等人于1978年发表了一个数学模型，该模型描述了腹腔内给药化疗药物的理论依据。许多作者提供了大量临床和实验证据支持德德里克的模型。卢卡斯等人以及托雷斯等人描述了药物从腹腔转运至门静脉和体循环所涉及的药代动力学。这些研究及其他研究催生了被称为腹膜血浆屏障（PPB）的药理学概念。PPB被描述为一种复杂的扩散屏障，由内皮、间皮和其间的间质以及血液和透析液中的液体组成。这种生理屏障限制了诸如丝裂霉素C、阿霉素和顺铂等亲水性药物从腹腔向血液中的吸收。
